{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":22,"n_cols":5,"rows_kept":22,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[11,2,11,3],[12,2,12,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910830428803321"]
[null,null,"Titolo",null,"Multi-drug resistance in cancer : mechanism and treatment strategies / / edited by Rishabha Malviya, Arun Kumar Singh, and Deepika Yadav"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, NJ : , : John Wiley & Sons, , [2023]"]
[{"$nulls":4},"©2023"]
[null,null,"ISBN",null,"1-394-20986-X"]
[{"$nulls":4},"1-394-20985-1"]
[null,null,"Descrizione fisica",null,"1 online resource (216 pages)"]
[null,null,"Disciplina",null,"614.5999"]
[null,null,"Soggetti",null,"Multidrug resistance"]
[{"$nulls":4},"Drug resistance in cancer cells"]
[{"$nulls":4},"Drug interactions"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Cover -- Title Page -- Copyright Page -- Contents -- Foreword -- Preface -- Acknowledgment -- Chapter 1 Multi-Drug Rmesistance in Cancer: Understanding of Treatment Strategies -- 1.1 Introduction -- 1.2 Both Congenital and Developed Resistance to Drugs -- 1.2.1 Intrinsic Resistance -- 1.2.2 Acquired Resistance -- 1.3 Drug-Resistance Mechanisms -- 1.3.1 Increased Efflux of Drugs -- 1.3.2 Impact on Medication Target -- 1.3.3 Improved DNA-Damage Repair -- 1.4 Senescence Escape -- 1.5 Epigenetic Alterations -- 1.6 Tumor Heterogeneity -- 1.7 Tumor Microenvironment -- 1.8 Epithelial to Mesenchymal Transition -- 1.9 Conclusion -- References -- Chapter 2 Understanding Different Mechanisms Involved in Cancer Drug Resistance: Proposing Novel Strategies to Overcome MDR -- 2.1 Introduction -- 2.2 Drug Resistance: Internal and External Variables -- 2.2.1 Phenotypic Variation of Tumors -- 2.2.2 Tumor Microenvironment -- 2.2.3 Cancer Stem Cells -- 2.2.4 Inactivation of the Anticancer Drugs -- 2.2.5 Multi-Drug Resistance -- 2.2.6 Increasing the Release of Drugs Outside the Cell -- 2.2.7 Reducing the Absorption of the Drugs -- 2.2.8 Inhibition of Cell Death (Apoptosis Pathway Blocking) -- 2.3 Improving the Pharmacokinetics -- 2.4 Changing the Aim of the Chemotherapy Agents -- 2.5 Improving the DNA Repair Process -- 2.5.1 Augmentation of a Gene -- 2.5.2 Epigenetic Altering Caused Drug Resistance -- 2.6 MicroRNA in Cancer "]
[{"$nulls":4},"Drug Resistance -- 2.7 Conclusion -- References -- Chapter 3 Molecular Mechanism of Multi-Drug Resistant Cancer Cells -- 3.1 Introduction -- 3.2 Types of Drug Resistance -- 3.3 Mechanisms of Drug Resistance -- 3.3.1 Drug Efflux via ABC Transporters -- 3.3.2 Permeability Glycoprotein/MDR-1 -- 3.3.3 Multi-Drug Resistance Protein -- 3.3.4 Breast Cancer Resistance Protein -- 3.4 Reduction in Drug Activity and Cellular Absorption."]
[{"$nulls":4},"3.5 Instability in the Genome and Medication Resistance -- 3.5.1 Mutation and Medication Target Alteration -- 3.5.2 Restoration of DNA Integrity -- 3.5.3 Resistant Genes and Epigenetic Modifications -- 3.5.4 Drug Resistance and Programmed Cell Death -- 3.6 RNA Interference Therapy -- 3.7 Methods of Physical Intervention to Treat MDR -- 3.8 Conclusion -- References -- Chapter 4 Natural Products for Clinical Management of Drug Resistant Cancer Cells -- 4.1 Introduction -- 4.2 Resistance Mechanisms -- 4.3 Antitumor Plants for Multi-Drug-Resistant Cells -- 4.4 Qualea Species and Their Medical Applications -- 4.5 Antitumor Activity of Qualea Grandiflora and Qualea Multiflora -- 4.6 Conclusion -- References -- Chapter 5 Understanding of Autophagy to Combat MDR During Anticancer Therapy -- 5.1 Introduction -- 5.2 Mechanisms of Autophagy -- 5.2.1 Phagophore Assembly -- 5.2.2 Autophagosome Formation and Maturation -- 5.2.3 Autolysosome Degradation -- 5.2.4 Core Regulator of Autophagy -- 5.3 Mechanisms of MDR -- 5.4 Correlation Between Autophagy and Multi-Drug Resistance -- 5.5 The Cytoprotective Effect of Autophagy in the Regulation of Multi-Drug Resistance -- 5.6 Increased Autophagy Facilitates Multi-Drug Resistance -- 5.7 Autophagy Inhibition Improves Chemotherapy in MDR Cancers -- 5.8 Overcoming MDR With Autophagic Cell Death -- 5.9 Autophagy Kills Apoptosis-Deficient MDR Cancer Cells -- 5.10 Autophagy Promotes Chemosensitivity -- 5.11 Conclusion -- References -- Chapter 6 Transporter Inhibitors: A Chemotherapeutic Regimen to Improve the Clinical Outcome of Colorectal Cancer -- 6.1 Introduction -- 6.2 CRC Transporters or ATP-Binding Cassette -- 6.2.1 ABC Transporter Family -- 6.2.2 ABC Transporters and CRC Initiation -- 6.2.3 ABC Transporters and the Resistance of Cancer Cells to Chemotherapy."]
[{"$nulls":4},"6.3 Clinical Evidence for the Function of ABC Transporters in CRC MDR -- 6.3.1 Intrinsic Drug Resistance in Colon Cancer Upregulation of P-gp at Detection -- 6.3.2 Proliferating Tumor Cells Have MRP1 on Their Surface -- 6.4 General Approaches -- 6.5 By Blocking Tyrosine Kinase Inhibitors from Inhibiting MDR Transporters -- 6.6 Components Produced from Natural Sources that Inhibit MDR Transporters -- 6.7 Inhibiting ABC Transporters in Other Ways for CRC MDR Circumvention -- 6.8 Challenges and Future Prospective -- 6.9 Conclusion -- References -- Chapter 7 Epithelial to Mesenchymal Transition (EMT): Major Contribution to Cancer Drug Therapy Resistance -- 7.1 Introduction -- 7.2 EMT and Tumor Resistance: In Vitro, In Vivo, and Clinical Trials -- 7.3 Tumor Microenvironment Regulates EMT -- 7.3.1 Hypoxia -- 7.3.2 The Extracellular Matrix -- 7.3.3 The Inflammatory and Immune Microenvironment -- 7.3.4 EMT Microenvironment: Medication Resistance -- 7.4 Drug Resistance and EMT Bioinformatics -- 7.4.1 Bioinformatics and Pharmacogenomics to Optimize Drugs and Targets and Identify Medication Resistance -- 7.4.2 Drug Resistance: Hereditary or Acquired -- 7.4.3 Therapies for EMT-Induced Medication Resistance -- 7.5 Conclusion -- References -- Chapter 8 Advances in Metallodrug-Driven Combination Therapy for Treatment of Cancer -- 8.1 Introduction -- 8.2 Cancer Treatment Using Combination Therapy -- 8.3 Combined Treatment with Metallodrugs for Cancer Treatment -- 8.3.1 Platinum Metallodrugs -- 8.4 Nonplatinum Metallodrugs -- 8.5 "]
[{"$nulls":4},"Conclusion -- References -- Chapter 9 Novel Strategies Preventing Emergence of MDR in Breast Cancer -- 9.1 Introduction -- 9.2 Breast Cancer Categorization and Epidemiological Studies -- 9.2.1 Treatment Options for Women With Breast Cancer -- 9.3 Multi-Drug Resistance in Breast Cancer -- 9.3.1 Breast Cancer Chemoresistance."]
[{"$nulls":4},"9.3.2 Multi-Drug Resistance and ABC Channels in Breast Cancer -- 9.4 Drug Efflux Transporters in Breast Cancer -- 9.4.1 Exocytosis Transporters in the Stem Cell Population of Breast Cancer -- 9.4.2 Drug Efflux Channel Upregulation in Breast Cancer -- 9.4.3 Techniques for Breast Cancer MDR Reversal -- 9.4.4 Direct Pharmacologic Inhibition With MDR Inhibitors -- 9.5 Excessive Synthesis or Overexpression of Transporters for the Expulsion of Drugs -- 9.6 Nanotherapeutic Approach for MDR Reversal -- 9.7 Breast Cancer's MDR Cure Problems and Future Outlook -- 9.8 Conclusion -- References -- Index -- EULA."]
[null,null,null,"Sommario/riassunto","This volume details the mechanisms underlying multi-drug cellular resistance and the targets of novel chemotherapeutic agents. Cancer is a major killer all over the world. Even with all the progress made, chemotherapy is still the mainstay of modern cancer treatment. The progression of the cellular defeat of numerous independent anticancer drugs in terms of their chemical structure is a major barrier to successful chemotherapy. This book contains nine chapters that cover topics such as: studying the mechanics of resistance to drugs by autophagy; studies to delineate the role of efflux transporters; expression of drug transporters; resistance to targeted therapies in breast cancer; advances in metallodrug driven combination treatment for cancer; and use of natural agents for the overcoming of cancer drug resistance."]